Trial Profile
BrUOG-PA-205 A phase I trial of GW572016 [lapatinib], gemcitabine and oxaliplatin for metastatic pancreaticobiliary cancer schema GSK study protocolGSK-103556
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Gemcitabine; Oxaliplatin
- Indications Biliary cancer; Pancreatic cancer
- Focus Adverse reactions
- 24 Mar 2009 Actual end date changed from Feb 2007 to Dec 2007 as reported by ClinicalTrials.gov.
- 15 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 31 Mar 2007 New trial record.